Kidney Health Report

Kidney Specialist Doctor Breaks Silence: "I've Been Prescribing the Wrong Solution for 20 Years"

"I watched too many people do exactly what they were told… and still walk into the dialysis conversation years later.'"

— Dr. Andrea Galvin, Nephrologist, Kidney Health Specialist

I watched my father's kidneys fail slowly while he did everything right.

His doctors never once mentioned what I am about to tell you.

My name is Dr. Andrea Galvin. I spent 20 years as a nephrologist — a kidney specialist. I have written thousands of prescriptions for ACE inhibitors, ARBs, and dietary restriction protocols for patients with chronic kidney disease.

I believed in them. I was trained by them. I followed the guidelines.

Then my father's eGFR dropped below 15 while doing everything his doctor — and I — told him to do.

He started dialysis on a Monday morning in March.

Monday. Wednesday. Friday. Four hours each session. The man who had walked every morning of his adult life — who had coached his grandchildren's football on Saturday mornings — sat in that chair and watched the clock while the machine did what his kidneys could no longer do.

He never walked every morning again.

He never coached another Saturday game.

And that is when I started asking questions I should have asked twenty years ago.

The Question That Changed Everything

My father did everything right.

He took his ACE inhibitor every single morning. His blood pressure medication every night. He reduced his sodium to below 1,500mg daily and tracked every gram. He weighed his protein portions on a kitchen scale. He attended every six-month appointment without missing one.

His eGFR at diagnosis: 61.

His eGFR the year he started dialysis: 12.

Nine years of perfect compliance. Every prescription filled. Every dietary restriction followed. Every appointment attended.

His eGFR fell by an average of 5 points every year anyway.

I went back through his records the night after his first dialysis session.

Every number tracked in the right direction for decline.

His eGFR falling steadily — 61, then 55, then 48, then 39, then 28, then 12 — despite perfect compliance with everything his doctor recommended.

His creatinine rising relentlessly — 1.1, then 1.4, then 1.7, then 2.1, then 2.8 — in the slow climb that every nephrologist learns to recognise as the trajectory that ends one way.

Nothing tracked in the direction of the mechanism underneath the decline.

Nobody had ever looked at what was driving the cellular damage producing those numbers.

Nobody had asked whether there was anything — any food, any natural compound, any intervention the pharmaceutical pathway simply did not have infrastructure to recommend — that might address the damage before it became the irreversible fibrosis those numbers represent.

I had twenty years of nephrology training and I had never been taught to ask that question either.

What They Don't Teach in Medical School

I started reading research I had filed away and never fully engaged with. Not pharmaceutical trials. Independent cellular research on kidney tissue decline.

What I found made me go back through years of patient files with different eyes.

Standard CKD management treats the symptoms of kidney decline. ACE inhibitors reduce pressure on the glomeruli. Dietary restrictions reduce the workload. Blood pressure management reduces downstream damage.

None of it addresses the three mechanisms that drive the cellular damage producing the declining eGFR in the first place.

Oxidative stress. The kidneys filter 200 litres of blood every day. That relentless demand generates more free radical activity in kidney tissue than almost any other organ in the body. As the body's antioxidant capacity declines with age the damage accumulates faster than kidney cells can repair it. The filtration capacity reduces. The eGFR falls. The creatinine rises.

Chronic inflammation. The TLR4/NF-kB inflammatory pathway — chronically activated in kidney disease — destroys the glomerular filtration structures from inside. Driven partly by uremic toxins the declining kidney cannot clear efficiently. The gut produces the toxins. The kidney fails to remove them. The toxins drive more inflammation. The inflammation causes more glomerular damage. The damage reduces clearance further. The eGFR keeps falling in a cycle that standard medication manages around but never interrupts at the source.

Fibrosis. When oxidative stress and inflammation damage kidney tissue the body responds by laying down scar tissue. Scar tissue cannot filter. Once established it is largely permanent. Every year of unaddressed cellular damage is another year of fibrosis — another point off the eGFR that will not come back regardless of how well the pharmaceutical management controls the symptoms above it.

My father's medication managed the pressure symptoms.

It did not stop the oxidative damage accumulating in his kidney cells.

It did not reduce the TLR4/NF-kB inflammation destroying his glomeruli.

It did not address the fibrosis accumulating silently in his kidney tissue while his eGFR fell from 61 to 12 and the appointments kept happening and the prescriptions kept being adjusted and nobody once asked what was driving the damage underneath the numbers.

And the research showing that a natural compound could address all three had been sitting in peer-reviewed journals for decades.

The Discovery I Almost Dismissed

A colleague in traditional medicine research sent me a paper I nearly deleted.

The subject line read: "Kidney function in Tibetan highland populations — anomalous findings in elderly subjects."

I almost did not open it.

I am glad I did.

Researchers had spent years studying the elderly populations of the traditional herding communities of the Tibetan plateau. Not a clinical population. Not people recruited for a study. People living at elevations above 3,500 metres in one of the most extreme environments on earth.

The Tibetan plateau sits higher than almost any inhabited place in the world. The air contains roughly 40% less oxygen than at sea level. Temperatures drop to minus 40 degrees in winter. The UV radiation at altitude is extraordinary. The physical demands of traditional herding life — moving animals across vast distances of high terrain, performing manual labour in extreme cold — are severe by every measure of human endurance.

By every model I used to predict age-related kidney decline these populations should have shown significant deterioration.

Their kidneys told a completely different story.

Elderly men and women in these communities showed eGFR values in their seventies and eighties that I would not have expected to see. Not slightly better than predicted. Meaningfully better. Values that made the researchers run the data again.

Creatinine levels that remained stable across age ranges where I routinely observe consistent increases in the patients I treat every day.

Not one or two outliers.

A pattern. Consistent across communities. Consistent across generations.

No dialysis infrastructure. No ACE inhibitors. No standard CKD protocol. No pharmaceutical management of any kind.

The research team spent years trying to explain it.

It was not genetics.

The researchers controlled for genetic variables rigorously. Other groups at similar altitudes with comparable genetic backgrounds did not show the same kidney function profile. The effect was specific to these communities and could not be attributed to ancestry.

It was not altitude itself.

Other high-altitude populations — communities in the Andean highlands, villages in Nepal and Bhutan at comparable elevations — did not show the same kidney function profile when the researchers controlled for dietary variables. Altitude was a constant. The kidney outcomes were not.

It was not physical activity.

Other traditionally active populations with physically demanding lifestyles showed normal age-related kidney decline. Activity alone did not explain it.

It was not reduced protein intake.

Dietary analysis showed protein consumption comparable to or exceeding other populations in the study. The low-protein hypothesis that standard CKD management is partly built on did not explain the data.

The researchers kept eliminating explanations.

Year after year. Every obvious variable first. Then the less obvious. Then the ones that seemed almost too simple to take seriously.

What they found — after years of eliminating everything else — was something that had been sitting in plain sight the entire time.

Something these communities consumed every single day. Something their grandparents consumed. Their great-grandparents. Going back further than anyone could trace in the written historical record. Something woven so deeply into the daily rhythm of life on the Tibetan plateau that it barely registered as a health practice.

A mushroom.

Cordyceps sinensis.

The caterpillar fungus.

Growing wild at elevations above 3,500 metres. A parasitic fungus that begins as a spore, finds its way into the body of a caterpillar larva buried beneath the soil, slowly replaces the larva's tissue across the winter, and pushes a thin orange fruiting body out of the ground each spring when the ice recedes.

Part insect. Part mushroom. One of the most unusual organisms on earth.

Tibetan herders had noticed what it did to their animals centuries before any researcher arrived with equipment. Animals grazing where Cordyceps grew were noticeably stronger. More resilient. The herders began consuming it themselves. Incorporating it into the traditional medicine that Tibetan practitioners had been refining for fifteen centuries.

Tibetan traditional medicine had been using Cordyceps specifically for kidney vitality and longevity for as long as written records existed on the plateau.

Not for energy. Not for athletic performance.

For the kidneys. Specifically. Deliberately. Consistently. Across fifteen centuries of documented traditional use.

The herders who consumed it every morning were not thinking about TLR4/NF-kB pathways or glomerular filtration rates.

They were thinking about living well on a harsh plateau for as long as their bodies would allow.

Their eGFR values told the story of what happens when you give kidneys what they actually need.

Wild Cordyceps sinensis from the Tibetan plateau now sells for up to $20,000 per kilogram. Tibetan foragers spend weeks at altitude collecting it by hand each spring. A single good harvest can fund a family for a year. The people who have lived closest to it have understood its value for fifteen centuries before any laboratory existed to explain why.

The researchers did not discover something new.

They finally measured something ancient.

Why This Mushroom Does What Medication Cannot

The Cordyceps research did not just confirm the population associations. It showed the specific mechanisms.

Cordycepin — the primary bioactive compound — directly suppresses the TLR4/NF-kB inflammatory pathway driving the glomerular destruction. In a published clinical trial Cordyceps militaris supplementation was associated with a 36.7% reduction in urinary protein in CKD patients over three months. Not managing the downstream effects of glomerular damage. Reducing the inflammatory destruction causing the damage itself. (PMC6462325)

The polysaccharides in Cordyceps protect kidney cell mitochondria from oxidative damage specifically. When mitochondrial function is protected oxidative damage slows. When oxidative damage slows eGFR decline slows with it.

A 2025 study in Frontiers in Pharmacology identified specific anti-fibrotic pathways in Cordyceps — protection against the scarring process that makes kidney decline permanent — and specific protection from the uremic toxins driving the inflammatory cycle. (PMC12839192)

A meta-analysis reviewing 15 studies involving 1,310 patients confirmed significant therapeutic effect of Cordyceps sinensis as an adjunctive intervention across multiple trial designs and patient populations. (PMC11747039)

None of these mechanisms are addressed by ACE inhibitors.

None by dietary restriction.

None by standard CKD management protocol.

They are addressed by a mushroom that Tibetan herders have been consuming for 1,500 years — and whose effects on the exact markers your doctor tracks have been documented in published peer-reviewed research.

The Tibetan elders on the plateau were not doing anything special.

They were eating breakfast.

The same breakfast their grandparents ate on the same frozen plateau for fifteen centuries.

Their kidneys told a different story.

We replaced that breakfast with a prescription.

And then spent decades wondering why the prescription was not producing the same outcomes.

I Tried It On My Most Difficult Patient

Her name was Margaret. 71 years old. Retired nurse. She came to me after her third consecutive eGFR decline in eighteen months.

Her eGFR at first appointment: 44.

Stage 3b. Creatinine at 1.9 and rising. Her previous doctor had told her the trajectory was normal for her age and that medication escalation was the appropriate next step.

She sat across from me and said: "I spent 35 years as a nurse. I know what normal for your age means. I want to know if there is anything else."

I showed her the Cordyceps research. The Tibetan plateau communities. The three mechanisms. The meta-analysis. I told her what I had found after going back through my father's records that night.

I told her to ask her GP for a UACR — urinary albumin-to-creatinine ratio — as a baseline before she started anything. It measures how much protein the glomeruli are leaking. It responds faster than eGFR. It shows what is happening at the cellular level before the eGFR result can confirm it.

She came back to me ten weeks later.

Her eGFR: 47. Up from 44.

Her UACR: down 34% from her baseline.

Her previous doctor had told her those numbers only moved in one direction.

They moved the other direction. On Margaret's blood work.

I cannot make clinical claims about what Cordyceps will do for any individual patient. I can show you the research. I can tell you what Margaret's numbers did. I can tell you what I wish I had known to tell my father nine years ago.

Why Most Cordyceps Products Don't Deliver What the Research Shows

This is the part that frustrated me most when I started looking at commercial products.

The clinical research uses specific forms of the mushroom. Fruiting body extracts. Hot-water extracted. Standardised to bioactive content.

The majority of Cordyceps supplements on the market use mycelium on grain.

Mycelium is the root network of the mushroom — not the fruiting body. Not what the Tibetan herders consumed. Growing mycelium on grain substrate is fast and cheap. The resulting product is mostly grain starch. The cordycepin content — the primary bioactive responsible for the TLR4/NF-kB suppression — is a fraction of what genuine fruiting body extract provides.

One analysis found that genuine Cordyceps militaris fruiting body extract contains up to 90 times more cordycepin than mycelium on grain products.

The Tibetan herders were not consuming mycelium on grain. They were consuming the actual mushroom. Fruiting body. Whole organism. Everything intact.

Before you purchase anything — four questions.

Is it fruiting body extract — not mycelium on grain?

Is it hot-water extracted for bioavailability?

Does it have a third-party Certificate of Analysis showing actual cordycepin content?

Is it standardised to active compound content — not just weight of powder?

Most products fail at least two of these. Many fail all four.

The Product I Now Recommend

What I Tell My Patients Now

I still prescribe when the clinical picture requires it. I still follow evidence-based protocols.

But I tell every patient the same thing before the medication escalation conversation becomes unavoidable.

Your routine blood panel already has the two numbers that tell you what is happening to your kidneys right now. eGFR and creatinine. Ask your doctor what they are. Write them down. Date them.

Then ask for a UACR at the same time.

Retest at six to eight weeks after starting. Let the numbers tell you whether the mechanism is working. Not a feeling. Numbers. The same numbers your doctor uses.

If your markers do not move — they offer a full refund. No questions asked.

I spent 20 years watching eGFR decline in patients who were never told about the research I have just shared with you.

I cannot undo those 20 years.

I watched my father do everything right for nine years.

I watched his eGFR fall from 61 to 12.

I watched Margaret's numbers move the other direction in ten weeks.

The Tibetan herders were not following a protocol.

They were eating breakfast.

The same breakfast their grandparents ate on the same frozen plateau for fifteen centuries.

Their kidneys told a completely different story.

My father deserved to know that.

You deserve to know it now.

I spent 20 years prescribing the wrong solution.

The mushroom was always there.

Fifteen centuries of Tibetan herders knew it.

The research confirmed it.

Nobody put it on the prescription pad.

Statements on this page are for educational purposes and are not medical advice. This product is not intended to diagnose, treat, cure, or prevent any disease. Customers should consult a qualified healthcare professional before starting any supplement, especially if they have kidney disease, take medication, are pregnant, or are under medical supervision.